Ameritas Investment Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ameritas Investment Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$184K	Buy	19,309 +1,809	+10%	+$14K	0.01%	1315
2025 Q4	$137K	Hold	17,500	–	–	﹤0.01%	1510
2025 Q3	$133K	Sell	17,500 -3,432	-16%	-$28.6K	﹤0.01%	1509
2025 Q2	$188K	Hold	20,932	–	–	0.01%	1329
2025 Q1	$157K	Hold	20,932	–	–	0.01%	1421
2024 Q4	$157K	Hold	20,932	–	–	0.01%	1475
2024 Q3	$159K	Buy	20,932 +2,100	+11%	+$16K	0.01%	1483
2024 Q2	$116K	Hold	18,832	–	–	﹤0.01%	1625
2024 Q1	$95.7K	Hold	18,832	–	–	﹤0.01%	1770
2023 Q4	$113K	Hold	18,832	–	–	﹤0.01%	1652
2023 Q3	$133K	Buy	18,832 +3,990	+27%	+$28.7K	0.01%	1453
2023 Q2	$104K	Hold	14,842	–	–	﹤0.01%	1573
2023 Q1	$124K	Hold	14,842	–	–	﹤0.01%	1397
2022 Q4	$158K	Buy	14,842 +902	+6%	+$11.2K	0.01%	1298
2022 Q3	$175K	Hold	13,940	–	–	0.01%	1122
2022 Q2	$147K	Hold	13,940	–	–	0.01%	1245
2022 Q1	$227K	Hold	13,940	–	–	0.01%	1109
2021 Q4	$193K	Hold	13,940	–	–	0.01%	1255
2021 Q3	$200K	Hold	13,940	–	–	0.01%	1199
2021 Q2	$220K	Sell	13,940 -1,112	-7%	-$15.1K	0.01%	1174
2021 Q1	$153K	Hold	15,052	–	–	0.01%	1382
2020 Q4	$112K	Hold	15,052	–	–	0.01%	1512
2020 Q3	$52K	Buy	15,052 +2,322	+18%	+$9.95K	﹤0.01%	1808
2020 Q2	$61K	Hold	12,730	–	–	﹤0.01%	1708
2020 Q1	$25K	Hold	12,730	–	–	﹤0.01%	2043
2019 Q4	$44K	Buy	12,730 +4,433	+53%	+$11.2K	﹤0.01%	1994
2019 Q3	$24K	Hold	8,297	–	–	﹤0.01%	2285
2019 Q2	$31K	Hold	8,297	–	–	﹤0.01%	2179
2019 Q1	$68K	Hold	8,297	–	–	﹤0.01%	1705
2018 Q4	$67K	Hold	8,297	–	–	﹤0.01%	1636
2018 Q3	$63K	Hold	8,297	–	–	﹤0.01%	1856
2018 Q2	$48K	Hold	8,297	–	–	﹤0.01%	2005
2018 Q1	$40K	Buy	8,297 +1,600	+24%	+$8.22K	﹤0.01%	2033
2017 Q4	$33K	Hold	6,697	–	–	﹤0.01%	2161
2017 Q3	$34K	Hold	6,697	–	–	﹤0.01%	2095
2017 Q2	$37K	Buy	6,697 +1,100	+20%	+$6.7K	﹤0.01%	2086
2017 Q1	$47K	Buy	+5,597	New	+$38.9K	﹤0.01%	1887

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Ameritas Investment Partners's BCRX Position: Q1 2026 in Review

Ameritas Investment Partners increased its BioCryst Pharmaceuticals (BCRX) stake by 10% in Q1 2026, buying an estimated $14K and bringing the position to 19,309 shares worth $184K. The position accounts for 0.01% of the portfolio, ranked #1315.

Ameritas Investment Partners first reported a position in BCRX in Q1 2017 and has held it in 37 quarters since. The position peaked at $227K in Q1 2022. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Ameritas Investment Partners held 19,309 shares of BioCryst Pharmaceuticals worth $184K as of Q1 2026.
Ameritas Investment Partners bought 1,809 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $14K.
BioCryst Pharmaceuticals made up 0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1315 holding.
Ameritas Investment Partners first reported a position in BioCryst Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
Ameritas Investment Partners's BioCryst Pharmaceuticals position peaked at $227K in Q1 2022.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.